365 related articles for article (PubMed ID: 25767292)
1. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.
Cotroneo E; Ashek A; Wang L; Wharton J; Dubois O; Bozorgi S; Busbridge M; Alavian KN; Wilkins MR; Zhao L
Circ Res; 2015 May; 116(10):1680-90. PubMed ID: 25767292
[TBL] [Abstract][Full Text] [Related]
2. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
4. Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats.
Nan X; Su S; Ma K; Ma X; Wang X; Zhaxi D; Ge R; Li Z; Lu D
J Ethnopharmacol; 2018 Apr; 216():175-183. PubMed ID: 29325918
[TBL] [Abstract][Full Text] [Related]
5. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
[TBL] [Abstract][Full Text] [Related]
7. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
[TBL] [Abstract][Full Text] [Related]
8. Cystamine Treatment Fails to Prevent the Development of Pulmonary Hypertension in Chronic Hypoxic Rats.
Markvardsen LK; Sønderskov LD; Wandall-Frostholm C; Pinilla E; Prat-Duran J; Aalling M; Mogensen S; Andersen CU; Simonsen U
J Vasc Res; 2021; 58(4):237-251. PubMed ID: 33910208
[TBL] [Abstract][Full Text] [Related]
9. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
10. Iron is associated with the development of hypoxia-induced pulmonary vascular remodeling in mice.
Naito Y; Hosokawa M; Sawada H; Oboshi M; Iwasaku T; Okuhara Y; Eguchi A; Nishimura K; Soyama Y; Hirotani S; Mano T; Ishihara M; Masuyama T
Heart Vessels; 2016 Dec; 31(12):2074-2079. PubMed ID: 27311944
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D
Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
13. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
14. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
Abid S; Houssaïni A; Mouraret N; Marcos E; Amsellem V; Wan F; Dubois-Randé JL; Derumeaux G; Boczkowski J; Motterlini R; Adnot S
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):304-12. PubMed ID: 24334871
[TBL] [Abstract][Full Text] [Related]
15. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
16. Proteinase-activated receptor 1 antagonism ameliorates experimental pulmonary hypertension.
Kuwabara Y; Tanaka-Ishikawa M; Abe K; Hirano M; Hirooka Y; Tsutsui H; Sunagawa K; Hirano K
Cardiovasc Res; 2019 Jul; 115(8):1357-1368. PubMed ID: 30423156
[TBL] [Abstract][Full Text] [Related]
17. Chrysin Alleviates Monocrotaline-Induced Pulmonary Hypertension in Rats Through Regulation of Intracellular Calcium Homeostasis in Pulmonary Arterial Smooth Muscle Cells.
Dong F; Zhang J; Chen X; Zhang S; Zhu L; Peng Y; Guo Z
J Cardiovasc Pharmacol; 2020 Jun; 75(6):596-602. PubMed ID: 32168153
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
19. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
[TBL] [Abstract][Full Text] [Related]
20. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
